Our Portfolio


MPNs and GVHD		Clinical Proof of Concept	Pivotal	Approved
Jakafi® (ruxolitinib) 1 JAK1/JAK2	Myelofibrosis², polycythemia vera², GVHD²			
ruxolitinib XR (QD) JAK1/JAK2	Bioequivalence and stability testing			
axatilimab ³ CSF-1R	3L+ chronic GVHD			
	1L chronic GVHD + ruxolitinib			
zilurgisertib ALK2	Myelofibrosis-associated anemia ± ruxolitinib			
INCB57643 BET	Myelofibrosis ± ruxolitinib			
INCA33989 mutCALR	Myelofibrosis or ET with CALR mutation ± ruxolitinib			
INCB160058 JAK2 ^{V617F}	JAK2 ^{V617F} -mutated myelofibrosis			

Dermatology and Other IAI

Opzelura® (ruxolitinib) cream JAK1/JAK2	AD², vitiligo ^{2,4}	•
ruxolitinib cream JAK1/JAK2	Pediatric AD, prurigo nodularis	•
	Hidradenitis suppurativa, lichen planus, lichen sclerosus	•
povorcitinib JAK1	Hidradenitis suppurativa, vitiligo	•
	Prurigo nodularis, chronic spontaneous urticaria, asthma	•
zilurgisertib ALK2	Fibrodysplasia ossificans progressiva	•

Partnered Programs


Olumiant® (baricitinib) ⁵ JAK1/JAK2	Rheumatoid arthritis ⁶ , COVID-19 ⁶ , AD ^{4,7} , alopecia areata ^{2,4,7}			INCB161734 KR
Tabrecta® (capmatinib)® MET	NSCLC with METex14 ⁶		•	
capmatinib [®] MET	Liver cancer	•		
axatilimab CSF-1R	Idiopathic pulmonary fibrosis ⁹			





Updated as of April 30, 2024

Please refer to local prescribing information for more information, including full safety information, on Incyte's marketed medicines, or on medicines marketed by Incyte's collaboration partners. 1. Marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis outside the U.S. 2. Approved in the U.S. 3. In collaboration with Syndax 4. Approved in Japan 8. Worldwide rights to capmatinib licensed to Novartis 9. IPF study currently led and funded by Syndax 10. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 11. Approved in Canada 12. European rights to Iclusig licensed from MacroGenics 14. Discovery collaboration with Agenus 15. Development in collaboration with Merus 1L, first-line; 2L+, second-line or later; 3L+, third-line or later; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IAI, inflammation and autoimmunity; IPF, idiopathic pulmonary fibrosis; mAb, monoclonal antibody; MLNs, myeloid/lymphoid neoplasms; MSI-H, microsatellite instability-high; mut, mutant; MZL, marginal zone lymphoma; NSCLC, non-small cell lung cancer; Ph+, Philadelphia chromosome-positive; QD, once daily; r/r, relapsed or refractory; XR, extended release.



SOLVE

ON.

Approved Products